Factors associated with errors in the heparin dose response test: recommendations to improve individualized heparin management in cardiopulmonary bypass

Abstract

Background:

A critical aspect of cardiopulmonary bypass (CPB) is to achieve full anticoagulation to prevent thrombosis and consumptive coagulation without using excessive amount of heparin. This can be achieved with heparin dose response (HDR) test in vitro to calculate an individualized heparin bolus to reach a target activated clotting time (ACT) and heparin concentration. However, we often observe that the measured ACT (mACT) with the calculated heparin bolus gives significant errors, both positive (mACT is higher than expected) and negative (mACT is lower), from expected ACT (eACT).

Methods:

We performed a retrospective study of 250 patients who underwent cardiac surgery to attain an error distribution of the mACT from eACT with calculated heparin bolus. In addition, it is aimed to identify possible patterns of baseline ACT (bACT), calculated heparin concentration (CHC) and HDR slope that are associated with the significant positive and negative errors.

Results:

We found that individualized heparin bolus by HDR test is consistently underestimated while it gave a significant number of positive and negative errors. Further analysis indicates that significant negative errors correlate with high bACT and slope and low CHC while significant positive errors with low bACT and slope and high CHC.

Conclusion:

The mACT can be substantially different from eACT. The accuracy of the HDR test appears to be dependent upon bACT, slope, and CHC. Based on our analysis, we provide several recommendations and a flow chart to improve the quality of individualized heparin management on CPB.

Keywords

cardiopulmonary bypass heparin dose response test expected vs measured activated clotting time individualized heparin management anticoagulation

Get full access to this article

View all access options for this article.

References

Jobes

Schwartz

Ellison

, et al. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg 1981; 31: 161–166.

Garvin

FitzGerald

Despotis

, et al. Heparin concentration–based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010; 111: 849–855.

Finley

Greenberg

Heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116: 1210–1222.

Finley

Heparin sensitivity and resistance: management during cardiopulmonary bypass. ASA refresh. courses in anesthesiol. 2015; 43: 58–65.

Ural

Owen

Pro: the Hepcon HMS should be used instead of traditional activated clotting time (ACT) to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothor Vasc An 2016; 30: 1727–1729.

Hattersley

PG.

Activated coagulation time of whole blood. JAMA 1966; 196: 436–440.

Jones

Nasrallah

Darling

, et al. The in vitro effects of aprotinin on twelve different ACT tests. J Extra Corpor Technol 2004; 36: 51–57.

Lobato

Despotis

Levy

, et al. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010; 139: 1665–1666.

Weitz

Hudoba

Massel

, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin 1990; 86: 385–391.

10.

Despotis

Joist

Hogue

Jr , et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995; 110: 46–54.

11.

Despotis

Joist

Hogue

Jr , et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902–908.

12.

Gravlee

Haddon

Rothberger

, et al. Heparin dosing and monitoring for cardiopulmonary bypass: a comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990; 99: 518–527.

13.

Gravlee

Rogers

Dudas

, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393–401.

14.

Levy

Montes

Szlam

, et al. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000; 90: 1076–1079.

15.

Despotis

Filos

Zoys

, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13–21.

16.

Mclaughlin

Dunning

In patients post cardiac surgery do high doses of protamine cause increased bleeding?

Interact Cardiovasc Thorac Surg 2003; 2: 424–426.

17.

Bull

Huse

Brauer

, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685–689.

18.

Noui

Zogheib

Walczak

, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27: 214–220.

19.

Meesters

Veerhoek

de Lange

, et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. Thromb Haemost 2016; 116: 251–261.

20.

Shigeta

Kojima

Hiramatsu

, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999; 118: 354–360.

21.

Fox

Gaines

Reed

Vehicles of heparin management: a comparison. J Extra Corpor Technol 1979; 11: 137–142.

22.

Aziz

Masood

Hoschtitzky

, et al. Does use of the Hepcon® point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg 2006; 5: 469–482.

23.

Ichikawa

Mori

Kodaka

, et al. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT. Perfusion 2017; 32: 474–480.

24.

Manual

. Hepcon® HMS Plus Hemostatis Management System. Multichannel Clot Timing Instrument with Automated Pipetting. p.116.

25.

Allen

Peng

Chen

, et al. Prediction of blood volume and adiposity in man from body weight and cube of height. Metabolism 1956; 5: 328–345.

26.

Garvin

Fitzgerald

Muehlschlegel

, et al. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010; 111: 856–861.

27.

Hilberath

Thomas

Smith

, et al. Blood volume measurement by hemodilution: association with valve disease and re-evaluation of the Allen Formula. Perfusion 2015; 30: 305–311.

28.

Hilberath

Smith

Jara

, et al. Blood volumes in cardiac surgery with cardiopulmonary bypass. Perfusion 2015; 30: 395–399.

29.

Lee

Gisnarian

Shann

KG.

Improved estimation of total blood volume can provide a reliable prediction of dilutional hematocrit and oxygen delivery during cardiopulmonary bypass. J Extra Corpor Technol 2019; 51: 67–72.

30.

Bajaj

Kuppuswamy

Saito

, et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869–8873.

31.

Maroney

Mast

AE.

Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher 2008; 38: 9–14.

32.

Ranucci

Isgrò

Cazzaniga

, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17: 199–204.